Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.19
Views: 684

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Dr Christopher Sweeney talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the ENZAMET trial looking at the use of enzalutamide as treatment for men with mHSPC who have received testosterone suppression.

He explains that enzalutamide is known to prolong the survival of men with castration resistant disease so the purpose of this trial was to study its success in the hormone sensitive setting.

Dr Sweeney reports that patients randomly received either enzalutamide or placebo with testosterone suppression and that after 3 years the overall survival rates were 80% with enzalutamide compared with 72% for placebo.

See the press conference here.

Read the news story here.

Watch a comment from Dr Neeraj Agarwal here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation